1. 1) Abe T., Kobayashi K., Nishikawa S., Yamada T., Hasegawa R., Sakuratani Y., Yamada H., Hirose A., Kamata E., Yoshida M., Sunouchi M., Honma M., Yamashita T., Sakai K., Yamazoe Y., Hayashi M., PHARM STAGE, 12, 39-47 (2012).
2. 2) Ankley G., Bennett R., Erickson R., Hoff D., Hornung M., Johnson R., Mount D., Nichols J., Russom C., Schmieder P., Serrrano J., Tietge J., Villeneuve D., Environ. Toxicol. Chem., 29, 730-741 (2010).
3. 3) Organisation for Economic Co-operation and Development. “Adverse Outcome Pathways, Molecular Screening and Toxicogenomics.”: 〈https://www.oecd.org/chemicalsafety/testing/adverse-outcome-pathways-molecularscreening-and-toxicogenomics.htm〉, cited 17 July, 2019.
4. 4) European Chemicals Agency, “Guidance on Information Requirements and Chemical Safety Assessment Chapter R.7a: Endpoint specific guidance,” Version 6.0, 2017.
5. 5) Brockmeier E., Hodges G., Hutchinson T., et al., Toxicol. Sci., 158, 252-262 (2017).